OBJECTIVE: Although bone marrow, liver, thymus (BLT)-humanized mice provide a robust model for HIV-1 infection and enable evaluation of cure strategies dependent on endogenous immune responses, most mice develop graft versus host disease (GVHD), limiting their utility for extended HIV cure studies. This study aimed to: evaluate the GVHD-resistant C57 black 6 (C57BL/6) recombination activating gene 2 (Rag2)γcCD47 triple knockout (TKO)-BLT mouse as a model to establish HIV-1 latency. Determine whether TKO-BLT mice could be maintained on antiretroviral therapy (ART) for extended periods of time. Assess the rapidity of viral rebound following therapy interruption. DESIGN: TKO-BLT mice were HIV-1 infected, treated with various ART regimens over extended periods of time and assayed for viral rebound following therapy interruption. METHODS: Daily subcutaneous injection and oral ART-mediated suppression of HIV-1 infection was tested at various doses in TKO-BLT mice. Mice were monitored for suppression of viremia and cellular HIV-1 RNA and DNA prior to and following therapy interruption. RESULTS: Mice remained healthy for 45 weeks posthumanization and could be treated with ART for up to 18 weeks. Viremia was suppressed to less than 200 copies/ml in the majority of mice with significant reductions in cellular HIV-1 RNA and DNA. Treatment interruption resulted in rapid viral recrudescence. CONCLUSION: HIV-1 latency can be maintained in TKO-BLT mice over extended periods on ART and rapid viral rebound occurs following therapy removal. The additional 15-18 weeks of healthy longevity compared with other BLT models provides sufficient time to examine the decay kinetics of the latent reservoir as well as observe delays in recrudescence in HIV-1 cure studies.
OBJECTIVE: Although bone marrow, liver, thymus (BLT)-humanized mice provide a robust model for HIV-1 infection and enable evaluation of cure strategies dependent on endogenous immune responses, most mice develop graft versus host disease (GVHD), limiting their utility for extended HIV cure studies. This study aimed to: evaluate the GVHD-resistant C57 black 6 (C57BL/6) recombination activating gene 2 (Rag2)γcCD47 triple knockout (TKO)-BLT mouse as a model to establish HIV-1 latency. Determine whether TKO-BLT mice could be maintained on antiretroviral therapy (ART) for extended periods of time. Assess the rapidity of viral rebound following therapy interruption. DESIGN: TKO-BLT mice were HIV-1 infected, treated with various ART regimens over extended periods of time and assayed for viral rebound following therapy interruption. METHODS: Daily subcutaneous injection and oral ART-mediated suppression of HIV-1 infection was tested at various doses in TKO-BLT mice. Mice were monitored for suppression of viremia and cellular HIV-1 RNA and DNA prior to and following therapy interruption. RESULTS:Mice remained healthy for 45 weeks posthumanization and could be treated with ART for up to 18 weeks. Viremia was suppressed to less than 200 copies/ml in the majority of mice with significant reductions in cellular HIV-1 RNA and DNA. Treatment interruption resulted in rapid viral recrudescence. CONCLUSION:HIV-1 latency can be maintained in TKO-BLT mice over extended periods on ART and rapid viral rebound occurs following therapy removal. The additional 15-18 weeks of healthy longevity compared with other BLT models provides sufficient time to examine the decay kinetics of the latent reservoir as well as observe delays in recrudescence in HIV-1 cure studies.
Authors: Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia Journal: J Virol Date: 2011-10-19 Impact factor: 5.103
Authors: Jenna B Honeycutt; William O Thayer; Caroline E Baker; Ruy M Ribeiro; Steven M Lada; Youfang Cao; Rachel A Cleary; Michael G Hudgens; Douglas D Richman; J Victor Garcia Journal: Nat Med Date: 2017-04-17 Impact factor: 53.440
Authors: Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240
Authors: Nina C Flerin; Ariola Bardhi; Jian Hua Zheng; Maria Korom; Joy Folkvord; Colin Kovacs; Erika Benko; Ronald Truong; Talia Mota; Elizabeth Connick; R Brad Jones; Rebecca M Lynch; Harris Goldstein Journal: J Virol Date: 2019-03-05 Impact factor: 5.103
Authors: George N Llewellyn; Eduardo Seclén; Stephen Wietgrefe; Siyu Liu; Morgan Chateau; Hua Pei; Katherine Perkey; Matthew D Marsden; Sarah J Hinkley; David E Paschon; Michael C Holmes; Jerome A Zack; Stan G Louie; Ashley T Haase; Paula M Cannon Journal: J Virol Date: 2019-05-01 Impact factor: 5.103
Authors: Melissa A Gawron; Mark Duval; Claudia Carbone; Smita Jaiswal; Aaron Wallace; Joseph C Martin; Ann Dauphin; Michael A Brehm; Dale L Greiner; Leonard D Shultz; Jeremy Luban; Lisa A Cavacini Journal: J Immunol Date: 2018-12-28 Impact factor: 5.422
Authors: Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2022-01-12
Authors: William Mu; Madhav Sharma; Rachel Heymans; Eleni Ritou; Valerie Rezek; Philip Hamid; Athanasios Kossyvakis; Shubhendu Sen Roy; Victor Grijalva; Arnab Chattopadhyay; Jeremy Papesh; David Meriwether; Scott G Kitchen; Alan M Fogelman; Srinivasa T Reddy; Theodoros Kelesidis Journal: AIDS Date: 2021-03-15 Impact factor: 4.632